

1 Comparing Three Evidence-Based Strategies to Reduce 2 Cardiovascular Disease Burden:

3 *An Individual-Based Cardiometabolic Policy Simulation*

4 **Author List:**

- 5 • Sylvia Lutze, MS¹
- 6 • Steve Bachmeier, MS¹
- 7 • Alison Bowman, MPH¹
- 8 • Nicole DeCleene, BS¹
- 9 • Hussain Jafari, BS¹
- 10 • Matthew Kappel, MS¹
- 11 • Caroline Kinuthia, MPH¹
- 12 • Paulina Lindstedt, MPH¹
- 13 • Megan Lindstrom, PhD¹
- 14 • Rajan Mudambi, BA¹
- 15 • Christian Razo, PhD^{1,2}
- 16 • Kjell Swedin¹
- 17 • Abraham Flaxman, PhD^{1,2,3*}
- 18 • Gregory Roth, MD, MPH^{1,2,4*}

19 *Co-senior authors

20 **Author Affiliations:**

21 ¹Institute for Health Metrics and Evaluation, University of Washington, Seattle

22 ²Department of Health Metrics Sciences, University of Washington, Seattle

23 ³Department of Global Health, University of Washington, Seattle

24 ⁴Division of Cardiology, Department of Medicine, University of Washington, Seattle

25 **Short Title:**

26 Individual-Based Cardiometabolic Policy Simulation

27 **Corresponding Author Contact:**

28 Sylvia Lutze

29 lutzes@uw.edu

30 (408) 823-3224

31 Institute of Health Metrics and Evaluation

32 Population Health Building/Hans Rosling Center

33 3980 15th Ave. NE, Seattle, WA 98195 USA

34 UW Campus Box #351615

35 **Word Count of Manuscript:**

36 6522

42 Comparing Three Evidence-Based Strategies to Reduce 43 Cardiovascular Disease Burden:

44 *An Individual-Based Cardiometabolic Policy Simulation*

45 Sylvia Lutze, Steve Bachmeier, Alison Bowman, Nikki DeCleene, Hussain Jafari, Matthew Kappel,
46 Caroline Kinuthia, Paulina Lindstedt, Megan Lindstrom, Rajan Mudambi, Christian Razo, Kjell Swedin,
47 Abraham Flaxman, Gregory Roth

48 Abstract

49 • **Background:** Understanding the real-world impact of clinical trials is important for
50 informing health care policy. This is particularly true when trials are designed to show changes in
51 surrogate endpoints such as changes in risk factors rather than events or mortality. We
52 developed an agent-based microsimulation that estimates the population-level benefits in each
53 US state for cardiometabolic health interventions shown to improve risk factors.

54 • **Methods:** We designed a large-scale, location-specific agent-based simulation model
55 with a population of 51 million *in silico* individuals and estimated results for the years 2023 to
56 2040 in 30-day steps for each of the 50 states and District of Columbia. Input data reflected
57 current cardiometabolic health in each state and the effects of interventions and risk factors on
58 outcomes. We constructed three health policy intervention scenarios based on successful
59 randomized controlled trials designed to improve cardiometabolic population health: improved
60 access to fixed-dose combination (FDC) antihypertensive medication, a pharmacist-led
61 intervention to increase adherence to statin and antihypertensives medications at the time they
62 are initiated (Pharmacy), and a community-based lifestyle and behavior intervention designed to
63 prevent diabetes (Community). Outcomes included myocardial infarction, ischemic and non-
64 ischemic heart failure, and ischemic stroke events, deaths, and disability-adjusted life years
65 (DALYs).

66 • **Results:** Our simulation included a representative population of the United States,
67 accurate at the age, sex, and state level, with individual people simulated over 17 years. By the

68 year 2040, the FDC intervention was estimated to have prevented 776,000 (95% UI 578,000–
69 956,000) CVD DALYs and 44,600 (95% UI 32,700–55,600) deaths annually. Reductions in
70 ischemic heart disease deaths accounted for 76.5% of the total reductions in CVD deaths. The
71 Pharmacist intervention prevented 170,000 (95% UI 129,000–208,000) CVD DALYs, and the
72 Community intervention prevented 152,000 (95% UI 128,000–173,000) CVD DALYs.

73 • **Conclusions:** A fixed-dose combination of antihypertensives could prevent 1.2% of total
74 CVD DALYs, with smaller benefits from adherence and lifestyle-focused programs and impact of
75 interventions varying by state. The greatest reduction was in incident myocardial infarctions and
76 ischemic heart disease deaths. Providing accurate population-level estimates at the state level
77 can help local health policy decision-makers implement the most impactful interventions.

78 Clinical Perspective:

79 What is new?

- 80 • Using person-level simulation, we have translated randomized trial results showing
81 improvements in blood pressure, BMI, fasting plasma glucose, and LDL-C, and adherence to
82 medication into real-world impact including forecasting cardiovascular disease events and
83 deaths for the United States through the year 2040.
- 84 • A national, agent-based microsimulation for all 50 US states and DC allows us to assess how risk
85 factor interventions will differentially affect demographic groups and locations.

86 What are the clinical implications?

- 87 • Broad adoption of fixed-dose combination medication for hypertension had the largest health
88 benefit in all states.
- 89 • Interventions to improve adherence to medications or promote behavior change led to smaller
90 reductions in disease burden.

- 91 • Direct comparison of the estimated real-world impact of clinical and community-based
92 interventions can guide ongoing efforts to reduce the population burden of cardiovascular
93 disease and resulting disparities.

94 Introduction

95 Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for
96 695,000 deaths annually,^{1,2} with up to a third of those estimated to be preventable.³ Large-scale health
97 policy interventions such as the federally sponsored Million Hearts program have been rolled out to
98 reduce cardiovascular disease burden, but impact has been limited.⁴ The strongest evidence supporting
99 interventions to improve CVD comes from randomized clinical trials, which have shown benefits through
100 medications, improved medication adherence, and behavioral changes. However, the real-world impact
101 of these trials can be challenging to predict because they are most commonly powered for changes in
102 surrogate endpoints such as risk factor levels, and their effect when implemented at scale in a state or
103 health system can be unclear. Tools that estimate population-level impact from CVD interventions can
104 provide policymakers with a realistic assessment of their choices and improve their ability to make
105 necessary trade-off decisions between interventions.

106 To guide public health decision-making, we developed a person-level agent-based simulation for the
107 entire United States. The simulation estimates the real-world impact of well-tested risk factor-modifying
108 interventions on death, disability, and disease burden for state and national populations. Person-level
109 agent-based simulation is a method borrowed from engineering and related fields that offers substantial
110 advantages over traditional health models such as compartmental or decision tree simulations. For
111 example, it can accurately represent complex, multi-step interventions common for cardiovascular
112 diseases or even apply multiple interventions to be delivered over time, while also incorporating both
113 the observed variation in individual response to therapies and uncertainty around that response.

114 In this analysis, we modeled 51 million individuals (“simulants”) to understand how interventions
115 might change observed levels of risk factors in each US state, and how this change would affect
116 cardiovascular events and deaths over the next two decades.

117 Methods

118 Overview

119 We constructed and ran an individual-based microsimulation for all 50 states and Washington, DC.
120 Individual-based microsimulation is a computer modeling approach in which a cohort of 51 million *in*
121 *silico* individuals was created with demographic and health characteristics, and those characteristics
122 were changed sequentially in steps that represented the passage of time. Our simulation represented all
123 adults over age 25 in each US state and ran in the simulated timeframe of 2023 through 2040. We
124 utilized data from the Global Burden of Disease (GBD) 2019 study and other sources to match patterns
125 of age, sex, metabolic risk factor exposure and burden, disease rate, mortality rate, and health care
126 delivery in each US state.⁵⁻⁸ We designed the simulation to examine major metabolic risk factors: levels
127 of systolic blood pressure (SBP), fasting plasma glucose (FPG), serum LDL cholesterol (LDL-C), and body
128 mass index (BMI), and common cardiovascular diseases: ischemic heart disease (IHD), ischemic stroke,
129 and both ischemic and non-ischemic heart failure. A high-level flow diagram can be seen in Figure 1,
130 with detailed methods, an illustrative flow diagram (eFigure 1), and a schematic showing the
131 relationship between risk factors and outcomes (eFigure 2) in the supplement. The study did not involve
132 enrollment of human participants and used only existing population-level data.

133 Input Data for the Simulation

134 Data for risk factor levels, disease incidence, and cause-specific mortality were obtained from the
135 GBD study, along with existing published studies, including national and state-level population health
136 surveys.⁵⁻⁸ The relationship between a simulant’s risk factor level and health outcomes, both initially and
137 after treatment, were based on estimates of effect size from the GBD study’s meta-analyses of risk

138 factor-outcome relationships.⁹ Further details on the GBD study's estimation of relative risks can be
139 found in the supplement and previous publication.⁶

140 At initialization of the simulation, each simulant received an age, sex, disease status, and location-
141 specific level of systolic blood pressure (in mmHg), low-density lipoprotein cholesterol (in mmol/L), body
142 mass index (in kg/m²), and fasting plasma glucose (in mmol/L) from GBD data. We calibrated health care
143 visit rates to the GBD health care utilization study.¹⁰ To determine use of blood-pressure-lowering and
144 cholesterol-lowering medications, we initialized simulants based on self-reported use in the National
145 Health and Nutrition Examination Survey (NHANES) and Behavioral Risk Factor Surveillance System
146 (BRFSS) data to reflect observed state variation in medication rates.^{11,12} Our model represented
147 prescription and up-titration rates seen in real-world clinical practice, including AHA/ACC guideline-
148 based practice as well as practices that diverge from that guidance.¹³⁻¹⁵ Our model also incorporated the
149 effect of therapeutic inertia, the resistance to starting or increasing medication frequently observed in
150 practice, using real-world rates reported in previously published studies.^{16,17} The biologic effect of
151 pharmacotherapies on risk factors was based on large meta-analyses pooling the observed effect size
152 across multiple studies.^{18,19} Real-world differences in patient adherence were included based on
153 Medicare Part D data and a systematic review of the published literature.^{20,21} A full list of input values
154 and data sources are included in supplement eTable 1.

155 Individual-Based Simulation

156 We used the inputs above to create a simulation of risk factor exposures and disease rates through
157 the year 2040. We modeled changes in the health of each simulant according to the following inputs: a)
158 age- and sex-specific risk factor levels,⁶ disease and mortality rates,⁵ b) rates of primary care visits for
159 risk factor screening,¹⁰ c) rates for the use of antihypertensive and lipid-lowering medications,¹¹ d) rates
160 of therapeutic inertia,^{16,17} and e) medication titration over time based on observed rates of follow-up
161 and medication adjustment.^{13-15,18-20}

162 We implemented this model using Vivarium, an open-source, Python-based simulation framework
163 for our baseline health model.²² The baseline health model estimates a possible future trend in
164 cardiovascular disease for each US state based on past CVD burden rates and expected changes in
165 population, similar to other published forecasts.²³ Published examples of models utilizing Vivarium can be
166 found elsewhere.^{24–26} Simulated individuals, at each time step, are subject to the probability of a disease
167 event, or health care event (appointment, medications prescribed, healthy individuals may experience
168 CVD events, individuals experiencing CVD events may recover or die), which is modified by their other
169 assigned attributes including age, sex, and cardiometabolic risk factor exposures. A high-level flow
170 diagram can be seen in Figure 1, with a more detailed version as eFigure 1 in the supplement and
171 medication effects on risk factors in eTables 2 and 3.

172 Health Policy Intervention Scenarios

173 While many approaches have been tested over the past several decades to improve cardiovascular
174 population health by modifying risk factors, for the purpose of this study we selected three
175 interventions shown in high-quality randomized controlled trials to be effective for large populations.
176 We intentionally selected interventions delivered in different locations (ambulatory clinics, pharmacies,
177 communities) and targeting different combinations of risk factors to demonstrate the comparative
178 effectiveness of substantially different interventions on a common set of cardiovascular outcomes. Also,
179 comparison across these diverse settings for interventions has been prohibitively expensive and
180 challenging to perform with prospective studies. We then modelled the impact of each intervention as if
181 it were rolled out to an entire state's population, to reflect the theoretical potential that could be
182 achieved with maximum uptake of each intervention. We compared the baseline scenario described
183 above to three counterfactual health policy intervention scenarios: a) broad adoption of a community-
184 based lifestyle and behavior intervention similar to the US Diabetes Prevention Program delivered to all
185 individuals who met the relevant entrance criteria of prediabetes (Community),^{27,28} b) broad adoption of

186 a pharmacist-based intervention to increase medication adherence when a medication for high blood
187 pressure or high cholesterol is first prescribed, delivered to all individuals who met the relevant
188 entrance criteria (Pharmacy),²⁹ or c) broad adoption of a fixed-dose combination antihypertensive
189 intervention delivered to all individuals who met the relevant entrance criteria (FDC).^{30–32} Intervention
190 effect reflects landmark trials that were designed with surrogate endpoints, cardiovascular risk factors,
191 as the primary outcome. We modeled each intervention’s effect, via those surrogate endpoints, on
192 myocardial infarction (MI), stroke, and heart failure event and mortality rates, as well as population-
193 level burden as DALYs.

194 Outcomes and Scenarios Analysis

195 For each scenario, we calculated rates of incident disease (myocardial infarction, stroke, heart
196 failure), cause-specific death, all-cause death, years lived with disability (YLDs, years lived in less-than-
197 ideal health), years of life lost (YLLs, years of life lost due to premature mortality), and disability-adjusted
198 life years (DALYs, the sum of YLLs and YLDs) in each state, stratified by age and sex. We define CVD
199 outcomes in this paper as the sum of ischemic stroke, ischemic heart disease, and heart failure. We
200 compared intervention scenarios by calculating the number and percentage of cause-specific cardiac
201 events, deaths, YLDs, YLLs, and DALYs averted compared to the baseline scenario. The simulation used
202 identical simulants for each scenario who have the same probability of disease and death.³³ State-level
203 results were summed to national results based on state population. Results were averaged for annual
204 values between 2025 and 2040 to capture the long-term impact of interventions once fully adopted.

205 Validation and Data Processing

206 We ensured that model inputs remained stable within the complex dynamics of the simulation’s
207 medications, CVD events, and mortality by comparing incidence, prevalence, and mortality rates for all
208 diseases, risk factor distributions, and risk factor–attributable burden against GBD values.^{5,6} Additionally,
209 we ensured health care visit rates, adherence rates, medication effects, and therapeutic inertia rates

210 remained stable over time.^{10,16–20} Lastly, we ensured that verified that changes in adherence and risk
211 factors seen in the simulation were the same as those seen in the RCT results.

212 In later years of the simulation, population sizes differ due to the interventions' cumulative effects
213 on lives saved. Capturing these increases in population are an important output of this type of
214 simulation work. For the sake of clarity, counts data throughout this paper are scaled to the baseline
215 population size. Further details are in the supplement.

216 Statistical Analyses

217 We included parameter uncertainty in the microsimulation by running 10 replications with
218 independent parameter values drawn from the posterior distribution of our input data, resulting in our
219 modeling the life course of 51 million simulants. We used this to quantify uncertainty in our results by
220 calculating the mean, range, and 95% uncertainty interval (95% UI) based on the different draw values.

221 Results

222 Estimated Reduction in Cardiovascular Disease DALYs

223 At the national level, the FDC intervention resulted in a 1.2% (95% UI 0.90–1.4%) reduction in CVD
224 DALYs annually compared to the baseline scenario, while the Pharmacy intervention and the Community
225 intervention resulted in 0.26% (95% UI 0.20–0.31%) and 0.23% (95% UI 0.20–0.26%) reductions,
226 respectively. There was an average annual reduction between 2025 and 2040 of 776,000 (95% UI
227 578,000–956,000) DALYs in the FDC scenario, 170,000 (95% UI 129,000–208,000) in the Pharmacy
228 intervention, and 152,000 (95% UI 128,000–173,000) in Community intervention nationwide (Table 1).

229 All states saw the highest impact from FDC interventions, with lower impacts from the Pharmacy
230 intervention and Community intervention (Figure 2). The mean annual reduction in CVD DALYs from FDC
231 varied between 1.5% and 0.97% across locations (Figure 2). For the Pharmacy intervention, the mean
232 reduction in CVD DALYs varied between 0.32% and 0.19%, and for the Community intervention, it varied
233 between 0.32% and 0.18%. Total DALYs averted by state can be found in eTable 7 in the supplement.

234 Interventions shifted the distribution of risk factors relative to the baseline scenario (Figure 3). We
235 report California, Illinois, and Florida here as examples. Simulants who received the FDC intervention
236 had an average 8.6 mmHg lower SBP in all states compared to the same simulants in the baseline
237 scenario. Simulants who received the Pharmacy intervention had an SBP 0.38 to 0.42 mmHg lower and
238 an LDL-C 0.33 to 0.34 mmol/L lower than baseline. Simulants who received the Community intervention
239 had a 0.15 mmol/L lower FPG and 1.2 points lower BMI in all states.

240 Ischemic Heart Disease

241 The FDC intervention resulted in a 2.3% (95% UI 1.7–2.8%) annual reduction in IHD DALYs, compared
242 to 0.55% (95% UI 0.39–0.66%) with the Pharmacy intervention and 0.37% (95% UI 0.32–0.42%) with the
243 Community intervention. The FDC resulted in a 3.0% (95% UI 2.1–3.8%) annual reduction in IHD
244 incidence and a 2.0% (95% UI 1.5–2.5%) decrease in IHD deaths. The Pharmacy intervention and the
245 Community intervention, respectively, had a 0.79% (95% UI 0.54–1.0%) and 0.37% (95% UI 0.31–0.45%)
246 reduction in IHD incidence, and a 0.48% (95% UI 0.33–0.59%) and 0.31% (95% UI 0.27–0.36%) reduction
247 in IHD deaths.

248 The FDC intervention scenario averted 57,700 (95% UI 34,700–87,600) cases of myocardial
249 infarction and 34,100 (95% UI 24,800–43,700) IHD deaths on average annually. The Pharmacy
250 intervention and the Community intervention scenarios averted 17,400 (95% UI 10,700–25,100) and
251 5,260 (95% UI 3,360–8,160) cases of myocardial infarction and 8,190 (95% UI 5,490–10,600) and 5,330
252 (95% UI 4,420–6,180) IHD deaths. Total myocardial infarction count annually can be seen in Figure 4.
253 State-level results are in eTables 5-7 in the supplement.

254 Stroke

255 The FDC intervention resulted in a 2.1% (95% UI 0.89–2.7%) annual reduction in stroke DALYs. This
256 led to 22,100 (95% UI 13,000–30,200) fewer strokes and 1,950 (95% UI 40–2,810) fewer stroke deaths
257 nationwide. The Pharmacy intervention and Community interventions, respectively, resulted in a 0.58%
258 (95% UI 0.36–0.85%) and 0.09% (95% UI -0.04–0.21%) reduction in stroke DALYs. This led to 5,530 (95%

259 UI 3,700–7,520) and 1,220 (95% UI 176–1,990) fewer strokes and 664 (95% UI 253–1,110) and 63 (95%
260 UI -76–229) fewer stroke deaths annually. Total stroke count annually can be seen in Figure 4. State-
261 level results are in eTables 5-7 in the supplement.

262 Heart Failure

263 There was a smaller reduction in heart failure cases compared to other CVD events (Figure 4). The
264 FDC intervention resulted in a 1.0% (95% UI 0.64–1.6%) annual reduction in heart failure DALYs. This led
265 to 21,600 (95% UI 10,100–40,300) fewer heart failure cases and 19,900 (95% UI 11,500–36,300) fewer
266 heart failure deaths nationwide. The Pharmacy intervention and Community intervention resulted in a
267 0.13% (95% UI 0.08–0.21%) and 0.34% (95% UI 0.30–0.40%) reduction, respectively, in heart failure
268 DALYs. This led to 1,680 (95% UI 216–4,240) and 6,470 (95% UI 5,330–8,250) fewer heart failure cases
269 and 1,950 (95% UI 522–4030) and 6,170 (95% UI 5,280–7,740) fewer heart failure deaths annually. Total
270 heart failure count annually can be seen in Figure 4. State-level results are in eTables 5-6 in the
271 supplement.

272 Age and Sex

273 Our input data were specific to 5-year age and sex groups, allowing us to assess how results might
274 differ by population. Younger age groups saw much less benefit from interventions compared to ages 65
275 and above for all scenarios (Figure 5). The figure shows DALY counts averted, with the greatest
276 reductions in 65–75- and 75–85-year-olds. Despite sex-specific risk factor and disease rate inputs, we did
277 not see sex differences in relative impact or ordering of the interventions our results.

278 Validation

279 Disease model inputs remained stable for the duration of the simulation, matching the empirically
280 estimated disease rates from the Global Burden of Disease study used to initialize the first year of the
281 simulation. Additionally, health care visit rates, adherence rates, medication effects, and therapeutic
282 inertia rates remained stable over time and matched desired inputs. The stability of disease rates and

283 health care activities is reassuring and shows that simulants continued to be exposed to a realistic
284 process across many years of the simulation.

285 Our results were largely aligned with the results from the RCTs used to design the interventions. For
286 example, the FDC intervention trials report medication adherence and change in SBP level, which were
287 included directly in our simulation. Our results found an average decrease in SBP of 8.6 mmHg in all
288 states analyzed 1 year into the simulation. The reference source FDC trials found similar results in blood
289 pressure reduction.^{31,32}

290 The intervention to increase medication adherence trial only reported change in adherence,
291 which we directly implemented and modeled in our simulation. Similarly, for the Community
292 intervention, we directly modeled changes in risk factors to match the initial and sustained drops seen in
293 the 10-year follow-up of the NDPP. Further comparisons of simulated and RCT results can be found in
294 eTable 4 in the supplement.

295 Discussion

296 We estimate 4.0 million CVD events and 3.1 million CVD deaths, for a total of 67.8 million CVD DALYs
297 in 2040 nationally. Our simulation suggests that substantial improvements in population health could be
298 achieved with effective and broad delivery of proven interventions. Broad adoption of a fixed-dose
299 combination antihypertensive regimen for the management of hypertension is estimated to prevent
300 101,300 cardiovascular events and 44,600 CVD deaths in the United States annually, and over 1.5 million
301 events and 600,000 deaths by the year 2040. A pharmacy-based intervention to increase medication
302 adherence is estimated to prevent 24,610 CVD events and 9,540 CVD deaths annually. A community-
303 based intervention for lifestyle modification is estimated to prevent 12,950 CVD events and 8,260 CVD
304 deaths annually. These latter two interventions achieved only about 25% of the reductions seen with the
305 FDC intervention, suggesting that improvements in efficacy of pharmacotherapies would have a larger
306 impact than broader adoption of the current federal program for lifestyle modification or interventions

307 targeting improved medication adherence. Federal and state planning for population health goals
308 should consider the relative benefits of interventions at the state and national level.

309 Our microsimulation emulated the intermediate outcomes found in 3 randomized clinical trials, and
310 converted that impact into DALYs, events averted, and deaths averted within specific populations,
311 including by sex, age, and state. These successful RCTs showed promising results, but rollout nationally
312 was limited. Here, we show the significant public health benefit possible if these interventions are
313 successfully scaled up. For example, successful implementation of the FDC intervention is estimated to
314 achieve just under 40% of the federal government goal of preventing 1 million heart attacks and strokes
315 over 5 years and would achieve the million reductions in approximately 13 years.⁴

316 Our health policy model is the first to provide separate forecasts for each US state. It also provides a
317 comparison between multiple interventions. Prior policy models have been used to examine CVD health
318 processes and outcomes.^{34–36} They have found similar-magnitude impacts for population-level
319 interventions but only for single populations or locations.^{37–39} A state-level health policy model can help
320 address decision-making at this important level of government. Recent years have seen state-level
321 decisions on Medicaid funding and women’s health care that have serious implications for public
322 health.^{40,41} Our model also can be updated with current disease rates with each update of the Global
323 Burden of Disease study.

324 We observed large differences between the FDC scenario and the Pharmacy and Community
325 scenarios. This impact gap reflects both the large effect size of the FDC intervention and the sizeable
326 number of people in the total population eligible for this treatment, compared with the pharmacy- and
327 community-based interventions. The FDC intervention results in larger reductions to SBP than have been
328 shown with behavioral or lifestyle changes alone. Additionally, both hypertension and visits to health
329 care providers are common in the US, meaning there were significantly more eligible people accessing

330 the FDC intervention than the Community intervention, even accounting for the limiting effects of
331 therapeutic inertia and nonadherence.⁴²

332 The Pharmacy intervention was the second most effective. This intervention was designed to
333 improve adherence rates to medications, resulting in a significant benefit for those simulants who began
334 receiving medications. However, because the intervention only impacted individuals who would have
335 been non-adherent, only 7% of antihypertensive medication users and 12% of cholesterol medication
336 users experienced a benefit. The Community intervention program was limited, by design, to those who
337 both have high BMI and are pre-diabetic, resulting in a smaller enrolled population size than the other
338 interventions, approximately 2.8% of simulants compared to 9.6% in FDC intervention. Future
339 community-based programs targeting behavior change should consider enrolling broader populations at
340 risk.

341 Overall, heart failure cases saw less reduction than stroke or myocardial infarction (Figure 4). There
342 are two reasons for this outcome. First, reductions in FPG and LDL-C have not been shown to reduce
343 incident HF in longitudinal studies once changes in IHD are accounted for, and therefore this was not
344 included in the simulation.⁴³⁻⁴⁷ The lack of observed effect may reflect limited sample size in large cohort
345 studies, which suggests that any possible missed effect is small. Second, the attributable fraction of
346 heart failure due to elevated SBP and BMI is much lower than in IHD and stroke. We estimated
347 approximately 50% of IHD or stroke cases are caused by elevated BMI or SBP, but only about 20% of
348 heart failure cases are caused by one of these risk factors.⁶

349 Our simulation utilizes data that are representative of the entire population in each state, which
350 includes variation between states due to demographic differences. Analysis at the state level allows us
351 to see how those demographic differences impact the relative impact from each intervention. The
352 intervention effect was similar across all states, but the magnitude of disease burden averted varied
353 widely. For example, Utah had the lowest rate of DALYs averted due to the FDC intervention, with

354 0.97%. Utah has one of the lowest average SBP levels of any state and one of the lowest rates of
355 hypertensive medication use. Fewer simulants received the FDC intervention, and SBP is responsible for
356 fewer CVD events in Utah, leading to a reduced impact.

357 Calibration of a simulation model to match real-world situations is essential to trusting the results of
358 a computer-based simulation of population health. For example, our model reliably reproduced the
359 expected results observed in RCTs. In the FDC intervention, our model found SBP reductions within the
360 confidence interval of 2 of the 3 trials for combination therapies reviewed.^{31,32} This is especially
361 important as the change in SBP was based on medication prescription and dynamics within the model,
362 not based on a direct effect of the intervention. This means that the complex health care system
363 designed to emulate real-world medication dynamics was successful in capturing sufficient detail.

364 Limitations

365 Given the scale of data inputs required for a simulation of this kind, some necessary input data were
366 limited in level of available detail or geographic representation. This was most apparent for inputs used
367 to model aspects of the health care system, such as therapeutic inertia or medication adherence.
368 Although we have age/sex/state-specific values for incidence, mortality rates, risk factors, and
369 medication rates, we assumed that the rates of adherence and therapeutic inertia did not vary by age,
370 sex, or state. For these limited components where we did not reflect possible variation in input data, we
371 might not fully capture expected variation in outcomes by sex, age, or state. We would not expect this
372 to bias our results at the aggregate, but our estimates could diverge from real-world when input is
373 limited in this way. We do note that there are very few population-level data available on medication
374 adherence or therapeutic inertia, and we do not know if age, sex, or location has a substantial impact on
375 these aspects of health care delivery. Also, our choice to estimate intervention impact using RCTs may
376 lead to overestimation of their impact due to differences between efficacy of an intervention among a
377 highly selected population enrolled in a trial and effectiveness in the general population. We accepted

378 this as a potential source of bias in order to inform the simulation with the most reliable and robust
379 estimates of each intervention's effect, based on estimates that due to randomization were unaffected
380 by either observed or unobserved confounding.⁴⁸

381 Conclusion

382 This simulation quantifies the potential public health benefit if effective interventions were to be
383 scaled up successfully at the state and national level. Broad adoption of a fixed-dose combination
384 antihypertensive regimen for the management of hypertension was estimated to prevent 101,300 CVD
385 events and 44,600 CVD deaths in the United States annually, and over 1.5 million events and 600,000
386 deaths by the year 2040. This simulation suggests that substantial improvements in population health
387 are achievable with effective and broad delivery of proven interventions.

388 References

- 389 1. Multiple Cause of Death Data on CDC WONDER. Accessed November 22, 2023.
390 <https://wonder.cdc.gov/mcd.html>
- 391 2. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association |
392 Circulation. Accessed November 22, 2023.
393 <https://www.ahajournals.org/doi/10.1161/CIR.0000000000001123>
- 394 3. Potentially Preventable Deaths from the Five Leading Causes of Death — United States, 2008–2010.
395 Accessed November 22, 2023. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6317a1.htm>
- 396 4. CDC. Million Hearts®. Centers for Disease Control and Prevention. Published May 5, 2023. Accessed
397 November 14, 2023. <https://millionhearts.hhs.gov/index.html>
- 398 5. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and
399 territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The*
400 *Lancet*. 2020;396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9
- 401 6. Murray CJL, Aravkin AY, Zheng P, et al. Global burden of 87 risk factors in 204 countries and
402 territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The*
403 *Lancet*. 2020;396(10258):1223-1249. doi:10.1016/S0140-6736(20)30752-2
- 404 7. Kenchaiah S, Sesso HD, Gaziano JM. Body Mass Index and Vigorous Physical Activity and the Risk of
405 Heart Failure Among Men. *Circulation*. 2009;119(1):44-52.
406 doi:10.1161/CIRCULATIONAHA.108.807289
- 407 8. Zhang Y, Vittinghoff E, Pletcher MJ, et al. Associations of Blood Pressure and Cholesterol Levels
408 During Young Adulthood With Later Cardiovascular Events. *J Am Coll Cardiol*. 2019;74(3):330-341.
409 doi:10.1016/j.jacc.2019.03.529
- 410 9. Zheng P, Afshin A, Biryukov S, et al. The Burden of Proof studies: assessing the evidence of risk. *Nat*
411 *Med*. 2022;28(10):2038-2044. doi:10.1038/s41591-022-01973-2
- 412 10. Moses MW, Pedroza P, Baral R, et al. Funding and services needed to achieve universal health
413 coverage: applications of global, regional, and national estimates of utilisation of outpatient visits and
414 inpatient admissions from 1990 to 2016, and unit costs from 1995 to 2016. *Lancet Public Health*.
415 2019;4(1):e49-e73. doi:10.1016/S2468-2667(18)30213-5
- 416 11. Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS).
417 National Health and Nutrition Examination Survey Data.
418 <https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear=2017>
- 419 12. CDC - BRFSS. Published January 9, 2024. Accessed January 25, 2024.
420 <https://www.cdc.gov/brfss/index.html>
- 421 13. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention
422 of Cardiovascular Disease: Executive Summary: A Report of the American College of

- 423 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*.
424 2019;140(11). doi:10.1161/CIR.0000000000000677
- 425 14. Byrd JB, Zeng C, Tavel HM, et al. Combination therapy as initial treatment for newly diagnosed
426 hypertension. *Am Heart J*. 2011;162(2):340-346. doi:10.1016/j.ahj.2011.05.010
- 427 15. Nguyen V, deGoma EM, Hossain E, Jacoby DS. Updated cholesterol guidelines and intensity of
428 statin therapy. *J Clin Lipidol*. 2015;9(3):357-359. doi:10.1016/j.jacl.2014.12.009
- 429 16. Turchin A, Goldberg SI, Shubina M, Einbinder JS, Conlin PR. Encounter Frequency and Blood
430 Pressure in Hypertensive Patients with Diabetes. *Hypertension*. 2010;56(1):68-74.
431 doi:10.1161/HYPERTENSIONAHA.109.148791
- 432 17. Goldberg KC, Melnyk SD, Simel DL. Overcoming inertia: improvement in achieving target low-
433 density lipoprotein cholesterol. *Am J Manag Care*. 2007;13(9):530-534.
- 434 18. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of
435 cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from
436 prospective epidemiological studies. *BMJ*. 2009;338:b1665. doi:10.1136/bmj.b1665
- 437 19. Descamps O, Tomassini JE, Lin J, et al. Variability of the LDL-C lowering response to ezetimibe
438 and ezetimibe + statin therapy in hypercholesterolemic patients. *Atherosclerosis*. 2015;240(2):482-
439 489. doi:10.1016/j.atherosclerosis.2015.03.004
- 440 20. Cheen MHH, Tan YZ, Oh LF, Wee HL, Thumboo J. Prevalence of and factors associated with
441 primary medication non-adherence in chronic disease: A systematic review and meta-analysis. *Int J*
442 *Clin Pract*. 2019;73(6):e13350. doi:10.1111/ijcp.13350
- 443 21. Part C and D Performance Data | CMS. Accessed January 30, 2024.
444 <https://www.cms.gov/medicare/health-drug-plans/part-c-d-performance-data>
- 445 22. Vivarium. <https://vivarium.readthedocs.io/en/latest/>
- 446 23. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United
447 States: a policy statement from the American Heart Association. *Circ Heart Fail*. 2013;6(3):606-619.
448 doi:10.1161/HHF.0b013e318291329a
- 449 24. Haddock B, Pletcher A, Blair-Stahn N, et al. Simulated data for census-scale entity resolution
450 research without privacy restrictions: a large-scale dataset generated by individual-based modeling.
451 *Gates Open Res*. 2024;8:36. doi:10.12688/gatesopenres.15418.1
- 452 25. Kannan A, Tsoi D, Xie Y, Horst C, Collins J, Flaxman A. Cost-effectiveness of Vitamin A
453 supplementation among children in three sub-Saharan African countries: An individual-based
454 simulation model using estimates from Global Burden of Disease 2019. Horton S, ed. *PLOS ONE*.
455 2022;17(4):e0266495. doi:10.1371/journal.pone.0266495
- 456 26. Young N, Bowman A, Swedin K, et al. Cost-effectiveness of antenatal multiple micronutrients
457 and balanced energy protein supplementation compared to iron and folic acid supplementation in

- 458 India, Pakistan, Mali, and Tanzania: A dynamic microsimulation study. *PLOS Med*.
459 2022;19(2):e1003902. doi:10.1371/journal.pmed.1003902
- 460 27. Diabetes Prevention Program Outcomes Study Research Group, Orchard TJ, Temprosa M, et al.
461 Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a
462 report from the DPP Outcomes Study. *Diabet Med J Br Diabet Assoc*. 2013;30(1):46-55.
463 doi:10.1111/j.1464-5491.2012.03750.x
- 464 28. National Diabetes Prevention Program | Diabetes | CDC. Published December 27, 2022.
465 Accessed February 1, 2023. <https://www.cdc.gov/diabetes/prevention/index.html>
- 466 29. Derose SF, Green K, Marrett E, et al. Automated Outreach to Increase Primary Adherence to
467 Cholesterol-Lowering Medications. *JAMA Intern Med*. 2013;173(1):38-43.
468 doi:10.1001/2013.jamainternmed.717
- 469 30. Thom S, Poulter N, Field J, et al. Effects of a Fixed-Dose Combination Strategy on Adherence and
470 Risk Factors in Patients With or at High Risk of CVD: The UMPIRE Randomized Clinical Trial. *JAMA*.
471 2013;310(9):918-929. doi:10.1001/jama.2013.277064
- 472 31. Muñoz D, Uzoije P, Reynolds C, et al. Polypill for Cardiovascular Disease Prevention in an
473 Underserved Population. *N Engl J Med*. 2019;381(12):1114-1123. doi:10.1056/NEJMoa1815359
- 474 32. Webster R, Salam A, de Silva HA, et al. Fixed Low-Dose Triple Combination Antihypertensive
475 Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension
476 in Sri Lanka: A Randomized Clinical Trial. *JAMA*. 2018;320(6):566-579. doi:10.1001/jama.2018.10359
- 477 33. Flaxman AD, Deason AW, Dolgert AJ, et al. Untangling uncertainty with common random
478 numbers: a simulation study. In: *Proceedings of the Summer Simulation Multi-Conference*.
479 SummerSim '17. Society for Computer Simulation International; 2017:1-12.
- 480 34. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary
481 heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. *Am J Public*
482 *Health*. 1987;77(11):1417-1426. doi:10.2105/AJPH.77.11.1417
- 483 35. Pandya A, Sy S, Cho S, Alam S, Weinstein MC, Gaziano TA. Validation of a Cardiovascular Disease
484 Policy Micro-simulation Model Using Both Survival and Receiver Operating Characteristic Curves. *Med*
485 *Decis Mak Int J Soc Med Decis Mak*. 2017;37(7):802-814. doi:10.1177/0272989X17706081
- 486 36. Hirsch G, Homer J, Evans E, Zielinski A. A System Dynamics Model for Planning Cardiovascular
487 Disease Interventions. *Am J Public Health*. 2010;100(4):616-622. doi:10.2105/AJPH.2009.159434
- 488 37. Kazi DS, Wei PC, Penko J, et al. Scaling Up Pharmacist-Led Blood Pressure Control Programs in
489 Black Barbershops: Projected Population Health Impact and Value. *Circulation*. 2021;143(24):2406-
490 2408. doi:10.1161/CIRCULATIONAHA.120.051782
- 491 38. Bibbins-Domingo K, Chertow GM, Coxson PG, et al. Projected effect of dietary salt reductions on
492 future cardiovascular disease. *N Engl J Med*. 2010;362(7):590-599. doi:10.1056/NEJMoa0907355

- 493 39. Bellows BK, Ruiz-Negrón N, Bibbins-Domingo K, et al. Clinic-based strategies to reach United
494 States Million Hearts 2022 blood pressure control goals: a simulation study. *Circ Cardiovasc Qual*
495 *Outcomes*. 2019;12(6):e005624. doi:10.1161/CIRCOUTCOMES.118.005624
- 496 40. Bossick AS, Brown J, Hanna A, Parrish C, Williams EC, Katon JG. Impact of State-Level
497 Reproductive Health Legislation on Access to and Use of Reproductive Health Services and
498 Reproductive Health Outcomes: A Systematic Scoping Review in the Affordable Care Act Era. *Womens*
499 *Health Issues*. 2021;31(2):114-121. doi:10.1016/j.whi.2020.11.005
- 500 41. Woolf SH. The Growing Influence of State Governments on Population Health in the United
501 States. *JAMA*. 2022;327(14):1331-1332. doi:10.1001/jama.2022.3785
- 502 42. CDC. Hypertension Prevalence in the U.S. | Million Hearts®. Centers for Disease Control and
503 Prevention. Published May 12, 2023. Accessed November 14, 2023.
504 <https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html>
- 505 43. Lee MMY, Sattar N, McMurray JJV, Packard CJ. Statins in the Prevention and Treatment of Heart
506 Failure: a Review of the Evidence. *Curr Atheroscler Rep*. 2019;21(10):41. doi:10.1007/s11883-019-
507 0800-z
- 508 44. Agarwala A, Pokharel Y, Saeed A, et al. The association of lipoprotein(a) with incident heart
509 failure hospitalization: Atherosclerosis Risk in Communities study. *Atherosclerosis*. 2017;262:131-137.
510 doi:10.1016/j.atherosclerosis.2017.05.014
- 511 45. Bell DSH, Goncalves E. Heart failure in the patient with diabetes: Epidemiology, aetiology,
512 prognosis, therapy and the effect of glucose-lowering medications. *Diabetes Obes Metab*.
513 2019;21(6):1277-1290. doi:10.1111/dom.13652
- 514 46. Nichols GA, Koro CE, Kolatkar NS. The incidence of heart failure among nondiabetic patients
515 with and without impaired fasting glucose. *J Diabetes Complications*. 2009;23(3):224-228.
516 doi:10.1016/j.jdiacomp.2007.10.001
- 517 47. Deedwania P, Patel K, Fonarow GC, et al. Prediabetes is not an independent risk factor for
518 incident heart failure, other cardiovascular events or mortality in older adults: Findings from a
519 population-based cohort study. *Int J Cardiol*. 2013;168(4):3616-3622.
520 doi:10.1016/j.ijcard.2013.05.038
- 521 48. Nordon C, Karcher H, Groenwold RHH, et al. The “Efficacy-Effectiveness Gap”: Historical
522 Background and Current Conceptualization. *Value Health*. 2016;19(1):75-81.
523 doi:10.1016/j.jval.2015.09.2938

524

525

526 **Table and Figure Information**

527 **Table 1: Average Cardiovascular Disease Disability-Adjusted Life Years, Deaths, and Events Averted**
 528 **Annually in the United States between 2025 and 2040**
 529

Intervention	Sex	CVD DALYs Averted	CVD Deaths Averted	CVD Events Averted		
				Myocardial Infarctions	Ischemic Strokes	Heart Failure Cases
FDC	Female	362,000 (276,000 to 440,000)	23,200 (17,100 to 28,700)	26,300 (15,000 to 41,600)	14,300 (7,600 to 19,600)	11,900 (6,240 to 21,100)
	Male	415,000 (303,000 to 517,000)	21,300 (15,600 to 27,000)	31,300 (19,600 to 45,800)	7,690 (4,880 to 10,600)	9,690 (3,840 to 19,200)
	Total	776,000 (578,000 to 956,000)	44,600 (32,700 to 55,600)	57,700 (34,700 to 87,600)	22,100 (13,000 to 30,200)	21,600 (10,100 to 40,300)
Pharmacy	Female	76,600 (58,000 to 92,000)	4,940 (3,690 to 6,080)	8,240 (5,010 to 12,500)	3,630 (2,340 to 5,040)	802 (-268 to 2,110)
	Male	94,000 (69,000 to 116,000)	4,590 (3,410 to 5,600)	9,170 (5,670 to 12,500)	1,890 (1,210 to 2,540)	884 (58 to 2,130)
	Total	170,000 (129,000 to 208,000)	9,540 (7,100 to 11,600)	17,400 (10,700 to 25,100)	5,530 (3,700 to 7,520)	1,680 (216 to 4,240)
Community	Female	64,800 (52,800 to 74,500)	3,860 (3,100 to 4,470)	1,960 (1,000 to 3,300)	719 (69 to 1,170)	3,240 (2,450 to 4,010)
	Male	87,600 (70,800 to 102,000)	4,400 (3,670 to 4,940)	3,300 (2,160 to 4,840)	495 (104 to 860)	3,220 (2,500 to 4,230)
	Total	152,000 (128,000 to 173,000)	8,260 (6,860 to 9,420)	5,260 (3,360 to 8,150)	1,220 (173 to 1,990)	6,470 (5,330 to 8,250)

530 *Caption: Total cardiovascular disease (CVD) disability-adjusted life years (DALYs), CVD deaths, and CVD events*
 531 *averted annually between 2025 and 2040 under each alternative intervention scenario. Includes a 95% uncertainty*
 532 *interval based on variation between simulation runs.*

533

534 **All figures uploaded separately as PDFs.**

535 **Figure 1: Flow of Simulants through the Model**

536 *Caption: High-level overview of the flow of simulants, including the health care system, interventions,*
 537 *risks affected, and outcomes. More detailed information including data input values can be found in*
 538 *eFigure 1.*

539 **Figure 2: Map Showing CVD DALYs Averted from Each Intervention by State**

540 *Caption: Percentage of cardiovascular disease (CVD) disability-adjusted life years (DALYs) averted under*
 541 *all intervention scenarios in each state.*

542 **Figure 3: Risk Factor Distribution Comparison between Scenarios in Three States**

543 *Caption: Change in risk factors between those who received each intervention and the same population*
 544 *in the baseline scenario. Shown for California, Illinois, and Florida. Only interventions that affect the risk*
 545 *factor are included in each graph. A version of Figure 2 for intention to treat can be found in eFigure 3 in*
 546 *the supplement.*

547 **Figure 4: Line Graph for Count of Incident CVD Events between Scenarios Over Time**

548 *Caption: Comparison of counts of total myocardial infarctions, heart failure diagnoses, and ischemic*
549 *strokes per year for each intervention scenario.*

550 **Figure 5: Stacked Bar Chart for CVD DALYs Averted between Scenarios by Age Group**

551 *Caption: Comparison of CVD DALYs averted in each age group and for each intervention scenario: fixed-*
552 *dose combination (FDC) antihypertensive, pharmacy intervention to increase medication adherence, and*
553 *community-based National Diabetes Prevention Program (NDPP).*

 Interventions

 Health Care System

 Risks

 Outcomes



Fixed Dose
Combination

Pharmacotherapy

Adherence to Medication

SBP

CVD Events
CVD Deaths
Time with
Disability



Pharmacy

Adherence to Medication

SBP

LDL-C

CVD Events
CVD Deaths
Time with
Disability



Community

Diet and Exercise


SBP

BMI


FPG

CVD Events
CVD Deaths
Time with
Disability


Percent of CVD DALYs Averted with FDC Scenario



Percent of CVD DALYs Averted with Pharmacy Scenario




Percent of CVD DALYs Averted with Community Scenario




Comparing Risk Exposures Across Scenarios for 3 Illustrative States

medRxiv preprint doi: <https://doi.org/10.1101/2024.08.01.24311387>; this version posted August 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


Systolic Blood Pressure in California



Systolic Blood Pressure in Illinois




Systolic Blood Pressure in Florida




FDC Scenario
Baseline


LDL Cholesterol in California



LDL Cholesterol in Illinois




LDL Cholesterol in Florida




Pharmacy Scenario
Baseline


BMI in California



BMI in Illinois




BMI in Florida




Community Scenario
Baseline


Fasting Plasma Glucose in California



Fasting Plasma Glucose in Illinois



Fasting Plasma Glucose in Florida




Community Scenario
Baseline


Comparing Incidence Across Scenarios

medRxiv preprint doi: <https://doi.org/10.1101/2024.08.01.24311387>; this version posted August 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


Count of Myocardial Infarctions in Females




Count of Myocardial Infarctions in Males




Count of Heart Failure in Females





Count of Heart Failure in Males



Count of Ischemic Strokes in Females




Count of Ischemic Strokes in Males




Comparing CVD DALYs Averted by Age Group and Sex between Scenarios


Community Scenario in Female




Community Scenario in Male




Pharmacy Scenario in Female



Pharmacy Scenario in Male



FDC Scenario in Female



FDC Scenario in Male

